AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
GW Pharmaceuticals - Re License Agreement.
(From AFX CNF)
RNS Number:4456T GW Pharmaceuticals PLC 22 March 2007 GW and Otsuka Receive Hart-Scott-Rodino Clearance for Sativex(R) US License Agreement 22 March 2007: GW Pharmaceuticals plc and Otsuka Pharmaceutical Co. Ltd today announce that they have each received early termination by the United States Federal Trade Commission and the Antitrust Division of the United States Department of Justice of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to the development and license agreement announced on 14 February 2007 granting Otsuka exclusive rights to develop and market Sativex(R), GW's lead product, in the …
-
- GW Pharmaceuticals and Otsuka Pharmaceutical Co Ltd agree three year...
-
News wire article from: Chemical Business Newsbase
June 30, 2010
700+ words
-
- GW Pharmaceuticals - Alliance with Otsuka.
-
News wire article from: Europe Intelligence Wire
February 14, 2007
700+ words
-
- Positive data in GW Pharmaceuticals's Sativex Phase IIb trial.
-
News wire article from: Chemical Business Newsbase
March 23, 2010
700+ words
-
- GW Pharmaceuticals teams up with Otsuka for US licensing of Sativex.
-
News wire article from: Europe Intelligence Wire
February 14, 2007
700+ words
-
- GW Pharmaceuticals: Receipt of milestone payment.
-
News wire article from: Chemical Business Newsbase
January 18, 2011
700+ words
